You are invited to an evening soirée in Atlanta.
Join the company of like-minded individuals, share your perspective among other trailblazers, and show your support for the legalization of psychedelic medicine.
Friday, October 13, 2017
Doors open at 7:30 pm
$150 (single) | $250 (pair)
Rick Doblin, Ph.D., is the founder and executive director of the Multidisciplinary Association for Psychedelic Studies (MAPS). His professional goal is to help develop legal contexts for the beneficial uses of psychedelics and marijuana, primarily as prescription medicines but also for personal growth for otherwise healthy people, and eventually to become a legally licensed psychedelic therapist.
Psychologist Barbara Rothbaum, Ph.D., is a leading PTSD researcher and currently serves as Principal Investigator of the ongoing MAPS-sponsored Phase 1 study on the effect of MDMA on startle testing in healthy volunteers, taking place at Emory University in Atlanta, Georgia.
Virgil Huston, poet and Iraq war veteran, overcame treatment-resistant PTSD after receiving MDMA-assisted psychotherapy as a participant in MAPS’ Phase 2 clinical research. Virgil is a vocal supporter of psychedelic medicine and its legalization for therapy and personal growth.
MAPS Founder and Executive Director, Rick Doblin, Ph.D., will hold an illuminating conversation about how the path to legalizing psychedelic medicine leads to his vision of a post-prohibition world; where psychedelics are used as prescription medicines, as valuable tools for inspiring creativity, for personal and spiritual growth, and for catalyzing resolutions to global and social conflicts.
Leading researchers will join in the discussion to highlight the progress of MAPS-sponsored clinical trials investigating MDMA-assisted psychotherapy as a treatment for posttraumatic stress disorder (PTSD).
Breakthrough Therapy Designation
Preliminary studies have shown that MDMA combined with psychotherapy can help people overcome PTSD. After careful review of these studies, the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to MDMA for the treatment of PTSD. By granting Breakthrough Therapy Designation, the FDA has agreed that this treatment may have a meaningful advantage and greater compliance over available medications for PTSD. Breakthrough Therapy Designation also means that the FDA will work closely with MAPS to complete Phase 3 trials, the final phase of research, as efficiently as possible.
Phase 3 trials require more clinical sites, more therapists, more patients, and more support. This research is crucial to receiving government approval of MDMA-assisted psychotherapy as a legal treatment, which would radically shift policy and public perception surrounding psychedelics.
There is a need unmet by modern psychiatry that psychedelic-assisted therapies can fill. By supporting groundbreaking research with psychedelic therapies, we can work together toward healing millions of people suffering from PTSD.
We can create this future together. Join us in opening the doors to new models for healing and personal growth. Proceeds from the event benefit MAPS’ research and education programs.
Special thanks to our host, Barbara Meyers, and our host committee member, Marsha Rosenbaum.
The Multidisciplinary Association for Psychedelic Studies (MAPS) is a non-profit research and educational organization that develops medical, legal, and cultural contexts for people to benefit from the careful uses of psychedelics and marijuana. Founded in 1986, MAPS’ highest priority is to develop MDMA-assisted psychotherapy into an FDA-approved prescription treatment for PTSD.
This event coincides with the International Drug Policy Reform Conference in Atlanta, Georgia, taking place from October 11-14, 2017.